New clinical data published in Archives of Surgery and Surgical Education and presented at the CLESF Annual Symposium demonstrate Preventogen’s effectiveness in lowering infection rates for trauma patients.
Key Highlights:
- Published Data: Clinical findings in Archives of Surgery and Surgical Education show reduced infection rates.
- New Patent: Recently secured patent strengthens Preventogen unique infection prevention technology.
- Industry Validation: Results presented at CLESF Annual Symposium highlight Preventogen impact.
- Patient Benefit: Improved recovery outcomes for trauma patients using external fixation.
St. Louis, MO (November 1, 2024) The article, titled “Preventogen: Shifting the Clinical Paradigm of Pin Site Care and Transosseous Wire Infections Associated with External Fixation in Limb Trauma & Reconstruction,” evaluated the use of Preventogen in 58 patients with a total of 468 pin insertion sites. The results revealed a pin site infection rate of just 0.9% in the Preventogen group, which is noteworthy considering the wide range of pin site infection rates reported in other medical literature, ranging from 3 to 80%. Furthermore, there were no readmissions or major complications associated with Preventogen use and no premature removal of wires or external fixators.
“The use of Preventogen as part of the pin-site care protocol has shown great promise in preventing infections at the source, leading to a notable shift in clinical practice paradigms,” said Edgardo Rodriguez-Collazo, the lead researcher and a global specialist in adult and pediatric lower limb deformity correction and orthoplastic surgery at Ascension Health Saint Joseph Hospital in Chicago, IL.
“We are extremely pleased with these results, which demonstrate Preventogen’s potential to significantly reduce infection rates in a challenging patient population,” said Brad Chartrand, CEO of Prevent-Plus. “We are committed to providing innovative solutions for unmet needs in patient care, and this peer reviewed research article further demonstrates how Preventogen can significantly improve clinical outcomes and hospital readmissions.”
The article concluded that pin site infections associated with external fixation remain a significant challenge with limited treatment options. Preventogen, a biodegradable and microbicidal liquid polymer, has proven effective when used as part of a comprehensive pin site care protocol. It is easy to use, well-tolerated, and compatible with established surgical principles.
The findings were presented at the CLESF Annual Symposium, hosted by Orthofix, a strategic partner of Prevent-Plus. CLESF surgeons generously volunteer their time, expertise, and resources to provide treatment for children in Latin America experiencing lower limb deformities. Preventogen supports CLESF’s mission by helping to ensure successful outcomes and improved quality of life for these children.
The implications of this article extend beyond the immediate patient population. Preventogen has the potential to improve trauma care worldwide, particularly in regions with limited resources or higher infection rates. By providing a safe and effective method for preventing pin site infections, Preventogen can contribute to better outcomes and reduced healthcare costs globally.
In addition to this and previous compelling studies, we were granted Patent number: 11986568 for a method to reduce fixation pin track infection rates issued on May 21, 2024, that underscores the innovative nature of our solution. The advocacy and positive feedback from surgeons who have used Preventogen and witnessed its impact on patient care further validate the urgent need for and effectiveness of our solution.
About Prevent-Plus and Preventogen:
Prevent-Plus manufactures and markets an FDA-cleared liquid polymer that provides both a microbicidal and physical barrier, making it well-suited for all individuals at risk of infection. Preventogen is Prevent-Plus’s hospital-grade product designed for use in clinical settings. This advanced wound care solution provides a non-antibiotic approach to infection prevention and optimal healing, killing microbes (bacteria, fungi, and viruses) on contact before forming a flexible, breathable polymer barrier. Preventogen has been clinically proven for a variety of both surgical and non-surgical wounds, significantly improving patient outcomes and quality of life.
